A detailed history of Kestra Advisory Services, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Kestra Advisory Services, LLC holds 7,785 shares of AXSM stock, worth $626,692. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,785
Previous 6,094 27.75%
Holding current value
$626,692
Previous $485,000 28.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$69.39 - $97.64 $117,338 - $165,109
1,691 Added 27.75%
7,785 $621,000
Q4 2023

Feb 14, 2024

SELL
$57.42 - $83.61 $103,470 - $150,665
-1,802 Reduced 22.82%
6,094 $485,000
Q3 2023

Nov 09, 2023

SELL
$69.25 - $82.21 $110,246 - $130,878
-1,592 Reduced 16.78%
7,896 $551,000
Q2 2023

Aug 11, 2023

SELL
$58.41 - $90.35 $18,340 - $28,369
-314 Reduced 3.2%
9,488 $681,000
Q1 2023

May 12, 2023

BUY
$58.39 - $75.0 $100,372 - $128,925
1,719 Added 21.27%
9,802 $604,000
Q4 2022

Jan 31, 2023

SELL
$39.94 - $79.72 $85,231 - $170,122
-2,134 Reduced 20.89%
8,083 $623,000
Q3 2022

Nov 01, 2022

SELL
$36.06 - $69.85 $142,509 - $276,047
-3,952 Reduced 27.89%
10,217 $456 Million
Q2 2022

Aug 12, 2022

BUY
$21.74 - $46.75 $99,438 - $213,834
4,574 Added 47.67%
14,169 $543,000
Q1 2022

Apr 26, 2022

BUY
$23.7 - $41.39 $79,181 - $138,283
3,341 Added 53.42%
9,595 $397,000
Q4 2021

Jan 20, 2022

SELL
$30.7 - $43.36 $3,991 - $5,636
-130 Reduced 2.04%
6,254 $236,000
Q3 2021

Oct 19, 2021

BUY
$19.91 - $68.26 $15,609 - $53,515
784 Added 14.0%
6,384 $210,000
Q2 2021

Jul 28, 2021

BUY
$50.63 - $73.5 $82,375 - $119,584
1,627 Added 40.95%
5,600 $377,000
Q1 2021

May 10, 2021

BUY
$55.91 - $81.44 $222,130 - $323,561
3,973 New
3,973 $224,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.45B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.